Prot #MK8226-003: A Phase 1b Randomized, Double-Blinded, Placebo-Controlled Multiple Rising Dose Clinical Trial to Study the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Intravenous MK-8226 in Patients with Moderate to Severe

    Project: Research project

    Project Details

    StatusFinished
    Effective start/end date1/21/141/21/17

    Funding

    • Merck Sharp & Dohme Corporation (Prot #MK8226-003)